BREAKING! Moderna Partners With OpenAI, Raising Concerns About Reliability And Safety Of Medical Data On ChatGPT From Now On!
Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 25, 2024 8 months, 6 days, 2 hours, 40 minutes ago
Medical News: Consumer groups, activists, medical and tech professionals and even the antivaxxers are now concerned about a recent announcement about a partnership between controversial pharma giant Moderna and OpenAI. While the partnership announcement merely details about Moderna getting OpenAI to modernize its organization with AI applications including chatbots etc, many experts say that its big pharma way of wanting to infiltrate AI platforms and control all medical data and information that is being disseminated or shared and even to collate data. The partnership is expected to see OpenAI getting millions from Moderna. There is also unvalidated speculations that OpenAI is also working with another clandestine off-shore company that is supposedly has the WEF, Bill Gates, Pfizer etc as proxy shareholders. It should be noted that Bill Gates already has its own AI chat platforms via MSN.
Moderna Partners With OpenAI, Raising Concerns About Reliability
And Safety Of Medical Data On ChatGPT From Now On!
According to a
Medical News release, Moderna, the biotechnology company behind the COVID-19 mRNA vaccines, has embarked on a transformative journey by partnering with OpenAI, a leader in artificial intelligence (AI) development. The news release claimed that this collaboration signifies a significant step towards integrating cutting-edge AI technologies into Moderna's daily operations, with the goal of enhancing productivity and driving innovation in the field of mRNA medicine.
https://www.accesswire.com/855900/moderna-and-openai-collaborate-to-advance-mrna-medicine
The Expanded Partnership: Custom-Built AI Chatbots for Moderna Employees
It was also claimed that this strategic move allows OpenAI to incorporate custom-built AI chatbots into Moderna’s workflows of its thousands of employees. This initiative aims to leverage AI's capabilities to streamline processes and facilitate data-driven decision-making across various departments within Moderna.
Leveraging AI Assistants for Enhanced Productivity
According to the new release, Moderna's investment in bespoke AI assistants underscores its commitment to optimizing operational efficiency and accelerating the development of new vaccine and drug products. By harnessing the power of AI, Moderna seeks to empower its workforce and enable them to navigate complex tasks more effectively.
Case Study: The Role of GPTs in Moderna's Operations
One of the standout features of this partnership is the deployment of Generative Pre-trained Transformers (GPTs) within Moderna's ecosystem. These GPTs, tailored to specific functions, have already demonstrated their value in areas such as dose selection for vaccine testing and contract analysis for legal teams.
-Dose ID GPT: Revolutionizing Vaccine Dose Selection
A
notable example is the Dose ID GPT, a pilot tool designed to validate vaccine doses selected by Moderna's clinical study team. By processing vast datasets and providing optimal dose recommendations, this AI-powered solution enhances decision-making processes and ensures the safety and efficacy of vaccine candidates.
-Legal Team Adoption: Rapid Integration of AI Tools
Moderna's legal team has been quick to embrace AI tools, showcasing the organization's readiness to embrace digital transformation. With AI-driven contract analysis and other capabilities, legal processes are streamlined, allowing for greater agility and risk mitigation.
The Technological Vision of Moderna: mRNA as Code
Moderna's embrace of AI aligns with its longstanding technological ethos, viewing messenger RNA (mRNA) as analogous to software and computer code. This perspective underscores the company's innovative spirit and its continuous quest for groundbreaking advancements in biotechnology.
Industry Trends: The Rise of Generative AI in Biopharma
Moderna's collaboration with OpenAI reflects broader industry trends, with leading biopharmaceutical companies exploring the potential of generative AI tools. Notable players like Amgen and Genmab are also leveraging AI to augment their workforce and drive innovation in drug discovery and development.
Startup Ecosystem: AI's Impact on Drug Discovery
Beyond established players, startups are harnessing AI to revolutionize drug discovery processes. The emergence of companies like Xaira Therapeutics, backed by substantial investment, highlights the growing interest and investment in AI-driven biotech solutions.
The Future of Moderna-OpenAI Collaboration: Advancing mRNA Medicine
Looking ahead, the Moderna-OpenAI partnership is poised to reshape the landscape of mRNA medicine and biotechnology. With ongoing co-innovation efforts and a shared vision of AI's transformative potential, both organizations are committed to pushing the boundaries of what's possible in healthcare and business.
ChatGPT Enterprise: Empowering Moderna's AI Culture
The deployment of ChatGPT Enterprise within Moderna signifies a shift towards a pervasive AI culture, where employees are equipped with advanced AI tools to tackle complex challenges. This holistic approach to AI integration fosters creativity, efficiency, and continuous learning within the organization.
AI-Powered Insights and Analytics
ChatGPT Enterprise's Advanced Analytics capabilities enable Moderna to derive actionable insights from vast datasets, driving data-driven decision-making and strategic planning. By leveraging AI for analytics, Moderna gains a competitive edge in optimizing processes and resource allocation.
Responsible AI Adoption: Ethical Considerations and Impact Assessment
As AI becomes increasingly integrated into Moderna's operations, the company claims to remains committed to responsible AI adoption. Ethical considerations, transparency, and impact assessments are integral parts of Moderna's AI strategy, ensuring that AI technologies are deployed ethically and responsibly.
Conclusion
The partnership between Moderna and OpenAI heralds a concerning era of AI-driven innovation in biotechnology and healthcare.
It is imperative that government agencies and regulatory entities interfere and supervise that there is no misuse of AI and AI based public platforms by the pharma giants. For the time being, individuals should be wary of any medical information obtained via ChatGPT platforms and should exercise caution when sharing any data on such platforms etc.
For the latest
Medical News, keep on logging to Thailand Medical News.
Share
Tweet
Share
